News

MCL-1 is one of the top-ten most amplified genes in all of human cancer and is vital to tumor development and cancer progression. In collaboration with the Broad

The current work builds upon the Company’s Cancer Immunotherapy Platform. This patent application covers intellectual property that provides a means of specifically inducing dendritic cells to internally generate

Cognate is a leader in the provision of cGMP manufacturing services and regulatory support to companies and institutions engaged in the development of regenerative medicine and cell-based products

The AACR-Bayer HealthCare Basic Cancer Research Fellowships represent a joint effort to provide critical support to postdoctoral and clinical fellows conducting basic cancer research at the earliest stages

The partnership expands Water Street’s pharmaceutical partnership program, which the firm established in 2013 as a new way to support corporations with leveraging their investment in developing pharmaceutical

VT-464 is an oral medication given without prednisone that may represent an improved therapy for men with CRPC and it works by selectively inhibiting CYP17 lyase, a target

MERS is caused by a coronavirus, which is related to the severe acute respiratory syndrome (SARS) virus and currently there is no vaccine or effective treatment for this

The approval was based on data from three Phase III studies, TARGET 1, TARGET 2 and TARGET 3 involving more than 3,000 patients. In these trials, Xifaxan 550mg

Fycompa is indicated to treat PGTC seizures in adult and adolescent patients from 12 years of age with idiopathic generalized epilepsy. Discovered and developed by Eisai, Fycompa is